Hepalink(SZ:002399)2022-12-06 09:46Group 1: Company Overview - The company, Shenzhen Hepalink Pharmaceutical Co., Ltd., was established in 1998 and primarily generates revenue from heparin raw materials, which received FDA approval in 2005 and EU registration in 2008 [1][2]. - Hepalink is the largest player in the heparin raw material industry, with increasing market concentration [2]. Group 2: Investment and Collaborations - Hepalink is collaborating with a Canadian company on RVX208, currently in Phase III clinical trials in Europe, targeting 2,500 clinical cases over 2.5-3 years [4]. - The company has established a joint venture in China with a monoclonal antibody firm, which has six products, with the fastest one entering Phase IIb clinical trials [4]. - Hepalink's subsidiary, Junshengtai, has completed Phase I clinical trials in Australia and will apply for Phase II trials in the U.S. [4]. Group 3: Market Dynamics and Pricing - Heparin prices rose from 2008 to 2010 due to supply shortages caused by the Baxter incident, but began to decline in 2011 due to increased supply and the approval of generic drugs [2]. - The company is focusing on new drug varieties starting from heparin and is also exploring innovative drugs in oncology and cardiovascular areas to address the ongoing decline in heparin prices [2].